المؤلفون: Victoria Atkinson, Céleste Lebbé, Jessica C. Hassel, Catalin Mihalcioiu, Cornelia Mauch, Ewa Kalinka-Warzocha, Ian M. Waxman, Ana Arance, Piotr Rutkowski, Kerry J. Savage, Vanna Chiarion-Sileni, Caroline Dutriaux, Micaela Hernberg, Abstr Act, Laurent Mortier, Catriona M. McNeil, Brian Sharkey, Caroline Robert, Dirk Schadendorf, Michele Maio, Christine Horak, Georgina V. Long, Lotta Lundgren-Eriksson, Benjamin Brady, Helen Gogas, Francesco Cognetti, Henrik Schmidt, Paolo A. Ascierto, Julie Charles

المصدر: Robert, C, Long, G V, Brady, B, Dutriaux, C, Maio, M, Mortier, L, Hassel, J C, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Savage, K J, Hernberg, M M, Lebbé, C, Charles, J, Mihalcioiu, C, Chiarion-Sileni, V, Mauch, C, Cognetti, F, Arance, A, Schmidt, H, Schadendorf, D, Gogas, H, Lundgren-Eriksson, L, Horak, C, Sharkey, B, Waxman, I M, Atkinson, V & Ascierto, P A 2015, ' Nivolumab in previously untreated melanoma without BRAF mutation ', The New England Journal of Medicine, vol. 372, no. 4, pp. 320-30 . https://doi.org/10.1056/NEJMoa1412082Test
New England Journal of Medicine; 372(4), pp 320-330 (2015)

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Dacarbazine, Programmed Cell Death 1 Receptor, Medizin, Phases of clinical research, Ipilimumab, Antineoplastic Agents, Pembrolizumab, ipilimumab-refractory metastatic melanoma, Gastroenterology, Disease-Free Survival, Young Adult, Double-Blind Method, Nivolumab, melanoma, ipilimumab-refractory metastatic melanoma, Internal medicine, Medicine, Humans, Survival rate, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Surgery, Survival Rate, Nivolumab, Cancer and Oncology, Female, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07253c758028e0b62a420832a391b6ecTest
https://pubmed.ncbi.nlm.nih.gov/25511188Test

المؤلفون: Christian H. Ottensmeier, Jeffrey S. Weber, Caroline Robert, Alfons J.M. van den Eertwegh, Axel Hoos, Jason Tian, Jessica C. Hassel, David F. McDermott, Walter J. Urba, Wallace Akerley, R. W. Weber, Geoffrey M. Nichol, Rene Gonzalez, John B. A. G. Haanen, Dirk Schadendorf, Julia Vaubel, Gerald P. Linette, Steven J. O'Day, Jedd D. Wolchok, David W. Hogg, F. Stephen Hodi, Christian Peschel, Joseph I. Clark, Paul Lorigan, Jose Lutzky, Céleste Lebbé, Michael Yellin, Jeffrey A. Sosman, Ian Quirt

المساهمون: Medical oncology, CCA - Innovative therapy

المصدر: New England Journal of Medicine, 363(8), 711-723. Massachussetts Medical Society
Hodi, F S, O'Day, S J, McDermott, D F, Weber, R W, Sosman, J A, Haanen, JB, Gonzalez, R, Robert, C, Schadendorf, D, Hassel, J C, Akerley, W, van den Eertwegh, A J M, Lutzky, J, Lorigan, P, Vaubel, J M, Linette, G P, Hogg, D, Ottensmeier, C H, Lebbe, C, Peschel, C, Quirt, I, Clark, J I, Wolchok, J D, Weber, J S, Tian, J, Yellin, M J, Nichol, G M, Hoos, A & Urba, WJ 2010, ' Improved Survival with Ipilimumab in Patients with Metastatic Melanoma ', New England Journal of Medicine, vol. 363, no. 8, pp. 711-723 . https://doi.org/10.1056/NEJMoa1003466Test
University of Manchester-PURE

مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Skin Neoplasms, Medizin, chemical and pharmacologic phenomena, Ipilimumab, Pembrolizumab, Kaplan-Meier Estimate, Cancer Vaccines, Double-Blind Method, Antigens, CD, Internal medicine, Medicine, Humans, CTLA-4 Antigen, neoplasms, Melanoma, business.industry, Hazard ratio, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Surgery, Sipuleucel-T, Treatment Outcome, Female, Nivolumab, business, Talimogene laherparepvec, Tremelimumab, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::879e8b03cb2c724046865af964c73435Test
https://pubmed.ncbi.nlm.nih.gov/21938386Test